Recent conference at the College de France (in French)
A review on hyaluronic acid for anticancer drug and nucleic acid delivery in ADDR
2015-12-04 - Hyaluronic acid (HA) is widely used in anticancer drug delivery, since it is biocompatible,biodegradable, non-toxic, and non-immunogenic; moreover, HA receptors are overexpressed on many tumor cells. Exploiting this ligand-receptor interaction, the use of HA is now a rapidly-growing platform for targeting CD44-overexpressing cells, to improve anticancer therapies. Together with colleagues from the University of Turin, we have reviewed the rationale underlying approaches, chemical strategies, and recent advances in the use of HA to design drug carriers for delivering anticancer agents. Comprehensive descriptions are given of HA-based drug conjugates, particulate carriers (micelles, liposomes, nanoparticles, microparticles), inorganic nanostructures, and hydrogels, with particular emphasis on reports of preclinical/clinical results. find more.
Walhan Alshaer presented today his thesis on liposome-bearing anti-CD44 aptamers for siRNA delivery to tumor cells
2016-03-21 - Walhan Alshaer from my group presented a thesis where his demonstrated to capability of liposomes to both load siRNA and be surface modified by an aptamer designed to target the CD44 receptor. Both in vitro and in vivo liposomes were able to deliver efficiently siRNA triggering the exctinction of luciferase expressed by breast cancer cells.